Quantcast
Last updated on April 23, 2014 at 11:40 EDT

Latest Erythropoietin Stories

2013-09-04 23:03:51

Medical Food Designed to Address the Increased Nutritional Requirements of Anemia Los Angeles, CA (PRWEB) September 04, 2013 Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia of chronic disease. The study consists of 30 patients randomized for treatment across...

2013-07-18 10:27:16

In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published July 17 in the Journal of the National Cancer Institute. To investigate the safety and...

2013-06-10 12:57:45

Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy. The discovery could spur development of drugs capable of increasing this protein's production without causing the severe side effects associated with glucocorticoids. "This research is medically...

2013-06-10 08:29:22

CARLSBAD, Calif. and VANCOUVER, British Columbia, June 10, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. announced today that Xenon has exercised its option to an exclusive worldwide license to XEN701, an antisense drug discovered in a collaboration between Isis and Xenon. For the license of XEN701, Isis earns a $2 million payment from Xenon. XEN701 is a drug candidate designed to inhibit the production of hepcidin, a target Xenon identified...

2013-06-03 16:26:40

-- Post-marketing study, presented at ASCO, included more than 2,300 patients -- LAKE FOREST, Ill., June 3, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today results from a post-marketing study of the company's European biosimilar epoetin, Retacrit(TM). This prospective, observational study met the primary endpoint, as defined by hemoglobin treatment response, in the management of...

2013-04-22 08:28:21

VANCOUVER, British Columbia, April 22, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013. The prestigious Gold Leaf Awards ceremony will take place on Tuesday, April 23 at the BIO International Convention in Chicago. Several thousand guests will be in attendance, representing the global life sciences community. "We are honored to be recognized by our national industry peers in this...

2013-03-11 15:08:13

Phase 3 findings published in NEJM provide answers about treatment with darbepoetin alfa Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients —darbepoetin alfa — does not improve patients' health, nor does it reduce their risk of death from heart failure. Results of the international study were presented at the American College of Cardiology's annual meeting in San...

2013-03-05 08:28:37

NES-ZIONA, Israel, March 5, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP). Upon issuance, the new patent will provide PROLOR with additional intellectual property protection that covers methods for decreasing body fat in humans through the use of hGH-CTP therapy....

2013-02-07 08:25:44

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts: (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO) Erythropoiesis-stimulating agents...

2013-02-04 08:25:36

WIXOM, Mich., Feb. 4, 2013 /PRNewswire/ -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate (SFP), its investigational iron-delivery drug currently in Phase 3...